What cardiologists need to know about cardiovascular magnetic resonance (CMR) acquire and interpret the scan. CMR is an interactive process that doesn't just require the operator to simply "push a button".
INTRODUCTION
Although considered by many to be a novel imaging technique CMR has been in clinical use for over 15 years and is part of routine cardiology practice in many countries. The "novelty" seems to come from lack of availability and therefore experience with the modality. This article aims to provide an explanation of how clinical cardiac MRI fits into the diagnostic armoury of the clinical cardiologist.
The commonly expressed benefits of CMR include terms such as "non-invasive", "non-ionising" and "safe"; however there are much more robust reasons to be mentioned. CMR often makes the diagnosis where other tests would fail mainly due its unique ability to characterise myocardial tissue but also due to the clarity of functional imaging.
(1) MR has significantly advanced our understanding of cardiac pathology and yielded new insights into management and prognosis.
HOW A CMR IS EXECUTED
CMR not only requires a magnet with appropriate cardiac software, but highly trained technicians, cardiologists and radiologists to Autumn 2012
Volume 9 • Number 2 dedicated images of the right heart, pulmonary arteries and aorta.
Tissue characterisation images are subsequently acquired in the same planes. These can include sequences to highlight water and thus tissue oedema (T2 weighted-STIR images), myocardial iron (T2*) and focal fibrosis (late gadolinium, inversion recovery imaging) as needed. Following the scan, the short axis stack is analysed with semi-automated, border detection software to give highly reproducible measurements of ventricular volumes and function. (3) (4) (5) (6) Chelated gadolinium-based contrast agents are used to characterise the myocardium and often for MR angiography. These agents do not contain iodinated material and are not contra-indicated in patients with previous reactions to radio-opaque contrast agents.
Gadolinium-based contrast agents are generally well tolerated with 1-5% patients experiencing minor nausea and transient headache.
Allergic reactions are rare and are reported to occur in every 10 000 -50 000 patients. A number of cases of nephrogenic systemic fibrosis (NSF) have now been reported in patients with end-stage renal failure receiving linear gadolinium agents. (7) (8) (9) NSF is much less likely with the newer cyclical compounds however, gadolinium administration is relatively contra-indicated in patients with impaired renal function and should be considered contraindicated in patients with severe kidney disease. That said, it is generally considered reasonable to administer cyclical gadolinium agents in patients with a GFR greater than 30ml/min if clinically indicated. Dialysis has not yet been proven to prevent NSF but can aid clearance of Gd-DTPA. (9) Gadolinium is taken up from the blood pool into the interstitium of tissue. The myocardial interstitial space is increased in areas of inflammation, infiltration and fibrosis. Gadolinium alters the T1 relaxation time of these areas thereby altering the signal obtained relative to the normal myocardium. These areas appear white (hyper-enhanced) as opposed to normal black (nulled) myocardium.
Different patterns of hyper-enhancement suggest different pathologies; for instance, myocardial infarction is seen beginning from the sub-endocardium however the distribution of hyper-enhancement in myocarditis is mid-wall or sub-epicardial.
(10)
SAFETY AND CONTRA-INDICATIONS
As a MR system consists of a large, static magnetic field in which radiofrequency (RF) energy is periodically released during imaging, there are possible hazards associated with its use. In general, the potential hazard of implants or devices is dependent on factors such as its degree of ferromagnetism, geometry, location in the body as well as the gradient and field strength of the imaging magnet. In assessing whether a particular patient should be subjected to a CMR scan, the main rule, as with other investigations in medicine, is to determine the risk-benefit ratio to the patient of the proposed study.
It is absolutely essential to carefully interview the patient prior to a MRI examination, and most centres would require a safety questionnaire to be completed. Whenever there is a concern about the safety of a patient with an implant, the CMR examination Pacemakers remain a contra-indication to cardiac MR currently, however most loop recorders are considered safe at 1.5T. Patients with prosthetic heart valves and coronary stents (as early as 24 hour after implantation) can be safely imaged at 1.5T. (11, 12) Some image degradation can occur with prosthetic material due to local disruption of the magnetic field.
Most, if not all orthopaedic implants, are safe. However, loose, metallic foreign bodies, cochlear implants and intracranial aneurysm clips are considered a strong contra-indication to MRI.
Newer MRI machines have larger bores however, claustrophobia can still be a problem. Minor degrees of anxiety can be overcome utilising blindfolds, prism spectacles or scanning prone. Sedation is generally avoided as patient cooperation is required although general anaesthesia can be used in specific circumstances.
WHEN AND WHY SHOULD CMR BE CONDUCTED?
The incremental value of CMR above echocardiography lies in the ability to characterise myocardial tissue and image the heart unencumbered by other thoracic structures eg ribs, lungs. Prescribed imaging plans eliminate foreshortening and ensure accurate cross-sectional measurement. The ability to clearly image the apex is obviously important when looking for mural thrombus or apical hypertrophic cardiomyopathy. (13) Although, a detailed review of each CMR indication is outside the scope of this article, the major current clinical uses are described in brief.
Tissue characterisation in heart failure
A major indication for CMR is to clarify the aetiology of heart failure. The formerly used gadolinium enhancement CMR technique (LGE-CMR) has potential roles in both diagnosis and prognosis of newly diagnosed heart failure patients. Specific patterns of fibrosis and scarring have been identified in many of the cardiomyopathy states (14, 15) and are summarised in Figure 1 . Ischaemic cardiomyopathy is characterised by sub-endocardial-based areas of late enhancement that correlate to irreversible myocardial necrosis on histopathology (Figure 2 ), a pattern consistent with the ''wave front phenomenon'' as described by Reimer and colleagues. (16) Patients who have non-ischaemic dilated cardiomyopathy may also have LGE-CMR evidence of scarring in up to 30% of cases; however, this is typically in a non-coronary distribution and frequently appears as a mid-wall striate. (14) Therefore, based on the presence and pattern of myocardial fibrosis, the aetiology of the cardiomyopathy can be accurately ascertained. Delineation of the underlying aetiology is of clinical value for patients with heart failure. In patients with ischaemic substrate causing their heart failure, the delineation of potential areas of myocardial ischaemia and viability is crucial to defining clinical management. In nonischaemic cardiomyopathy, extensive mid-wall fibrosis at presentation of symptoms, is indicative of a worse prognosis and a poorer response to standard heart failure therapy. Essentially, these studies found that the likelihood of improvement in regional function after revascularisation decreased progressively as the transmural extent of LGE before revascularisation increased. (18) This assessment is generally used to guide revascu- 
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larisation, but can also be used to plan resynchronisation therapy ("dead meat don't beat" i.e. one cannot pace non-viable scarred myocardium).
One of the key determinants of prognosis in ischaemic LV
dysfunction is left ventricular end-diastolic volume and ejection fraction (EF). Kim, et al. utilising LGE-CMR, (19) and Rizello, et al.
employing DSE, (20) Firstly, it can show that acute myocarditis (often with no clear viral prodrome clinically) is present. A combined CMR approach using T2-weighted imaging and contrast enhanced T1 weighted images, provides high diagnostic accuracy and is a useful tool in the diagnosis and assessment of patients with suspected acute myocarditis. (26) LGE in the setting of myocarditis has a "non-ischaemic" pattern, typically affecting the sub-epicardium and the mid-myocardial wall. This focal hyper-enhancement becomes diffuse over a period of days to weeks, then decreases during healing and may become invisible after recovery. Occasionally, the CMR reveals the diagnosis to be acute myocardial infarction even with relatively normal coronary arteries at angiography. Thirdly, CMR can show/ confirm the diagnosis of Stress (Takotsubo) cardiomyopathy. (27) The characteristic patterns of oedema settle quickly in the above conditions and prompt imaging is recommended to increase diagnostic yield. Achieving an accurate diagnosis has obvious benefits for future management and life/health insurance purposes.
Adult congenital heart disease
Due to the flexibility and quality of the images obtainable, CMR is particularly well suited to imaging congenital heart disease.
These patients often have poor echo windows and the right heart is notoriously difficult to assess fully. Serial follow up of great vessels and right heart dimensions is important when planning 
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Volume 9 • Number 2 In a large, prospective study, Greenwood, et al. very elegantly demonstrated the superiority and high diagnostic accuracy of CMR over SPECT in the detection of coronary heart disease. (29) They studied 752 patients with suspected coronary heart disease with multi-parametric CMR and Single-Photon Emission Computed Tomography (SPECT). X-ray coronary angiography was the reference standard. Multi-parametric CMR had a sensitivity of 86.5% (vs 66%), specificity of 83% (vs 82%) and negative predictive value of 90.5% (vs 79%). Several single-centre studies and a published multicentre trial have compared perfusion CMR favourably (sensitivities >90%, specificity around 80 -85%) to existing nuclear methods (SPECT) or invasive cardiac catheterisation for the detection of myocardial ischaemia in the setting of chronic chest pain. (30) A negative CMR perfusion in patients presenting with chest pain without ECG changes or cardiac biomarker abnormality, have an excellent short to mid term prognosis. The temporal resolution of CMR is currently limited which reduces the ability to detect small hypermobile structures such as vegetations. The sequelae of endocarditis such as root abscesses can be assessed however. (32) Echocardiography remains supreme in the evaluation of valvular lesions however CMR can complement echo in cases where the degree of severity is unclear such as aortic regurgitation. Volumetric differences can be used to calculate regurgitant fractions in isolated valvular lesions and in combination with flow measurements in more complex cases. The same techniques can be used to assess shunting in congenital heart disease.
Finally, the multiple facets of CMR make the modality invaluable in the assessment of pericardial pathology and cardiac masses.
Tumours can be reliably distinguished from other masses such as thrombus and often the type of tumour can be revealed by tissue characterisation sequences. Conflict of interest: none declared.
REST STRESS FIGURE 4: CMR-Stress perfusion imaging.
Perfusion defect in the inferior segment (arrow).
